FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a modified oligonucleotide that targets human androgen receptor (AR) to inhibit androgen receptor levels in the cell, and can be used in medicine. Obtained modified oligonucleotide and its pharmaceutically acceptable salt are used in the composition to inhibit androgen receptor levels in the cell, and to inhibit proliferation or growth of cancer cells such as prostate cancer, breast cancer, ovarian cancer, stomach cancer, or bladder cancer.
EFFECT: due to its structure and mechanism of action, the oligonucleotide enables to target the androgen receptor mRNA and induce antiproliferative responses in the cell.
20 cl, 146 tbl, 34 ex
Title | Year | Author | Number |
---|---|---|---|
CONJUGATED ANTISENSE COMPOUNDS AND USE THEREOF | 2014 |
|
RU2697152C2 |
COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
CANCER TREATMENT | 2013 |
|
RU2689548C2 |
COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | 2015 |
|
RU2703411C2 |
ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
COMPOSITIONS AND METHODS | 2014 |
|
RU2686080C2 |
COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | 2014 |
|
RU2670614C9 |
MODULATORS OF COMPLEMENT FACTOR B | 2014 |
|
RU2662967C2 |
FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
Authors
Dates
2018-10-23—Published
2013-10-11—Filed